title: Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus.
abstract: OBJECTIVE
  To evaluate the efficacy of HangAm-Plus (HAP) on stage IV metastatic gastric cancer by analyzing the treated patients' overall survival outcome.
  
  
  METHODS
  Following the study eligibility, overall survival and one year survival rate of 44 stage IV metastatic gastric cancer patients who visited East-West Cancer Center (EWCC) were analyzed. The study consisted of two arms: HAP treatment only (n=18) and combined treatment of concurrent conventional chemotherapy and HAP (n=26). Patient characteristics by gender, age, surgical intervention, Eastern Cooperative Oncology Group (ECOG) score, treatment duration (< 4 weeks or [Symbol: see text]4 weeks), and lines of the chemotherapy received were assessed. Treatment related side effects were also assessed.
  
  
  RESULTS
  The median survival of combined group was longer (10.0 months) than that of HAP group (5.1 months). One-year survival rate of combined treatment group and HAP group was 38.5%±9.5% and 33.3%±11.1%, respectively (P>0.05). One-year survival rate of those received more and less than 4-week treatment was 57.1%±18.7% and 8.3%±8.0%, respectively (P=0.001).
  
  
  CONCLUSIONS
  The study supports the safety and potential efficacy of HAP treatment in prevention of chemo-related side effects for stage IV metastatic gastric cancer treated with conventional chemotherapy. Further studies are needed to investigate and confirm the results before applying the treatment in clinical settings.
authors.affiliation: East-West Cancer Center, Dunsan Oriental Hospital of Daejeon University, 1136 Dunsandong Seogu Daejeon, 302-122, Soul, Korea.
authors.forename: Jae-Woo
authors.initials: JW
authors.lastname: Park
authors.forename: Jeungwon
authors.initials: J
authors.lastname: Yoon
authors.forename: Chong-Kwan
authors.initials: CK
authors.lastname: Cho
authors.forename: Yeon-Weol
authors.initials: YW
authors.lastname: Lee
authors.forename: Hwa-Seung
authors.initials: HS
authors.lastname: Yoo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004365:Drugs, Chinese Herbal / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016019:Survival Analysis; D055815:Young Adult
chemical_list: D004365:Drugs, Chinese Herbal; C000592150:HangAm-Plus